Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

  • Phase 3 trials for chronic weight management planned for initiation in the second half of 2026
  • Petrelintide demonstrated double-digit weight loss with placebo-like tolerability in the ZUPREME-1 Phase 2 trial
  • Zealand Pharma and Roche aim to unlock the full value potential of petrelintide providing a highly tolerable option for people living with overweight and obesity

Copenhagen, Denmark, April 29, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced formal endorsement to advance petrelintide, an amylin analog for chronic weight management, into Phase 3 trials with its partner Roche. The initiation is planned for the second half of 2026.